Dr. Jochen Knolle

Director, JCK Consult, Managing Director Pharvaris and Senior Advisor, TVM Capital

Jochen’s experience spans 30 years in the pharmaceutical industry, and encompasses every aspect of drug discovery, development and registration. Jochen was named as inventor on more than 100 patents and author of more than 60 publications. He was named as inventor of Quinapril and Firazyr.

From 1978 to 1998, Jochen worked in several functions in the central pharmaceutical research unit of Hoechst AG and Hoechst-Marion-Roussel (HMR). In 1998, Jochen left HMR to join Axys Pharmaceuticals (now Celera) in San Francisco, where he served as VP for Medicinal Chemistry and structural biology. From 2001-2008, Jochen was the Chief Scientific Officer and Head of R&D in the management board of Jerini AG in Berlin, Germany. In 2001, Jochen in-licensed Icatibant, a former research project of his, from Aventis. In 2008, Icatibant was approved in the EU and is marketed now in more than 40 countries including the US under the trade name Firazyr. While at Jerini, Jochen facilitated and managed collaborations with Merck, Kos Pharmaceuticals and Abbott, academic collaborations, private financing rounds and the IPO of Jerini at the German Stock Exchange Frankfurt in 2005. In 2008, Shire acquired Jerini. After completion of the transaction, Jochen resigned from the management board of Jerini in October 2008 and established JCK Consult.

In addition to his consultancy activities, Jochen acts as a board member for the Charité CRO, Berlin, Germany, and Anchor Therapeutics, Boston, Massachusetts, USA, as a board observer at Noxxon, Berlin, Germany, and as a Scientific Advisory Board member of Bicycle Therapeutics, Cambridge, UK, and OMEICOS Therapeutics, Berlin, Germany, and as Senior Advisor for TVM Capital, Munich, Germany. Jochen studied chemistry in Göttingen and Münster. After a post doc in the laboratory of the Nobel Laureate E.J. Corey at Harvard University, Jochen joined the pharmaceutical unit of Hoechst AG in 1978.